AU6085099A - Antiviral combinations comprising lamivudine and abacavir - Google Patents

Antiviral combinations comprising lamivudine and abacavir

Info

Publication number
AU6085099A
AU6085099A AU60850/99A AU6085099A AU6085099A AU 6085099 A AU6085099 A AU 6085099A AU 60850/99 A AU60850/99 A AU 60850/99A AU 6085099 A AU6085099 A AU 6085099A AU 6085099 A AU6085099 A AU 6085099A
Authority
AU
Australia
Prior art keywords
abacavir
lamivudine
antiviral combinations
antiviral
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60850/99A
Other languages
English (en)
Inventor
Nathaniel A. Brown
Lynn D. Condreay
Douglas Fraser Gray
Marc Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU6085099A publication Critical patent/AU6085099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU60850/99A 1998-09-18 1999-09-17 Antiviral combinations comprising lamivudine and abacavir Abandoned AU6085099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9820417.5A GB9820417D0 (en) 1998-09-18 1998-09-18 Antiviral combinations
GB9820417 1998-09-18
PCT/EP1999/006885 WO2000016779A1 (en) 1998-09-18 1999-09-17 Antiviral combinations comprising lamivudine and abacavir

Publications (1)

Publication Number Publication Date
AU6085099A true AU6085099A (en) 2000-04-10

Family

ID=10839131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60850/99A Abandoned AU6085099A (en) 1998-09-18 1999-09-17 Antiviral combinations comprising lamivudine and abacavir

Country Status (7)

Country Link
EP (1) EP1113803A1 (ja)
JP (1) JP2002526449A (ja)
KR (1) KR20010075202A (ja)
CN (1) CN1317971A (ja)
AU (1) AU6085099A (ja)
GB (1) GB9820417D0 (ja)
WO (1) WO2000016779A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520024A (en) 2000-02-29 2005-03-24 Bristol Myers Squibb Co Low dose entecavir formulation and usein treating hepatitis B virus infection
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
AU2003239088B2 (en) * 2002-06-27 2006-11-02 Medivir Ab Synergistic interaction of abacavir and alovudine
CN103221037A (zh) * 2010-11-12 2013-07-24 葛兰素惠尔康制造业私人有限公司 新药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
CO4970782A1 (es) * 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
JP2002526449A (ja) 2002-08-20
EP1113803A1 (en) 2001-07-11
CN1317971A (zh) 2001-10-17
GB9820417D0 (en) 1998-11-11
WO2000016779A1 (en) 2000-03-30
KR20010075202A (ko) 2001-08-09

Similar Documents

Publication Publication Date Title
HK1036455A1 (en) Antiviral purine derivatives
AU3289299A (en) Antiviral agents
AU3706399A (en) Phosphodiesterase iv-inhibiting diazepinoindoles
AU1527499A (en) Pen
AU1937199A (en) Printable interfaces and digital linkmarks
IL141844A0 (en) Antiviral combinations
AU2377097A (en) Antiviral ricin-like proteins
AU6680998A (en) Benzanthrone compounds and antiviral uses thereof
AU6085099A (en) Antiviral combinations comprising lamivudine and abacavir
AU9261198A (en) Antiviral agent
AU5515299A (en) 9-dialkylamino purinone derivatives
AU1873499A (en) Semi-submersible structure
AU5103299A (en) Photocleavable nucleoside base
AU1042701A (en) Antiviral combinations
ZA975565B (en) Antiviral combinations
AU6191999A (en) Antiviral combinations
GB9821000D0 (en) Antiviral combinations
ZA987425B (en) Phenylethanolaminotetralin derivatives and bronchodilators
AU8857998A (en) Pen
AU9000598A (en) Writing utensil
AU5686900A (en) Antiviral tetrahydroisichinolinsulfonamides
AU2407799A (en) Propelling pencil
AUPP100097A0 (en) Body board with adjustable fins
GB9719866D0 (en) Antiviral Combinations
GB9719883D0 (en) Antiviral combinations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase